Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination probiotic product containing Bacillus licheniformis and Bifidobacterium bifidum, both of which are well-studied probiotic bacteria. Bacillus licheniformis is a gram-positive, spore-forming bacterium known for its resilience and ability to produce digestive enzymes such as proteases, amylases, and cellulases. Bifidobacterium bifidum is an anaerobic bacterium commonly found in the human gut microbiota and associated with various health benefits. Together, these probiotics act primarily by modulating the gut microbiome, enhancing intestinal barrier function, reducing inflammation through downregulation of pro-inflammatory cytokines (such as IL-1α, IL-6, IL-8), upregulation of anti-inflammatory cytokines (such as IL-10 and TGF-beta), supporting immune regulation (including modulation of Th2-driven responses), inhibiting oxidative stress pathways, and improving gastrointestinal health during pathogen invasion or inflammatory conditions[2][5]. This combination has been studied for its potential benefits in gastrointestinal disorders such as ulcerative colitis[1][2], where it may help induce remission or reduce disease severity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bacillus licheniformis + bifidobacterium bifidum.